CX3CR1-Mediated Akt1 Activation Contributes to the Paclitaxel-Induced Painful Peripheral Neuropathy in Rats

Area of Science:

• Neuroscience
• Pharmacology
• Oncology

Background:

• Paclitaxel is a vital chemotherapy agent but causes dose-limiting painful peripheral neuropathy.
• The mechanisms driving paclitaxel-induced neuropathic pain are not well understood.

Purpose of the Study:

• To investigate the role of the CX3CR1/Akt1 signaling pathway in paclitaxel-induced neuropathic pain.
• To identify potential therapeutic targets for managing this chemotherapy side effect.

Main Methods:

• Paclitaxel administration in a preclinical model.
• Assessment of CX3CR1 and phosphorylated Akt1 expression in dorsal root ganglia (DRG) and spinal dorsal horn.
• Pharmacological inhibition of Akt1 pathway (MK-2206, LY294002) and CX3CR1 (neutralizing antibody).
• Evaluation of pain-related behaviors (mechanical allodynia, thermal hyperalgesia).

Main Results:

• Paclitaxel treatment upregulated CX3CR1 and phosphorylated Akt1 in DRG and spinal dorsal horn.
• Inhibition of Akt1 significantly reduced paclitaxel-induced pain behaviors.
• Blocking CX3CR1 prevented Akt1 activation and alleviated pain behaviors.

Conclusions:

• The CX3CR1/Akt1 signaling pathway plays a critical role in paclitaxel-induced painful peripheral neuropathy.
• Targeting the CX3CR1/Akt1 pathway presents a promising strategy for preventing and reversing paclitaxel-induced neuropathic pain.